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and Azienda Ospedaliera; and b Spinal Unit, Azienda Ospedaliera-Universitaria Careggi, Florence, ItalyObjective: To evaluate post-thawing sperm parameters in a large series of men cryopreserving for different cancers and oligospermia.
Design: Retrospective observational study.
Setting: Semen cryopreservation laboratory.
Patient(s): Six hundred twenty-three patients undergoing semen cryopreservation for cancer or oligospermia who discontinued
banking.
Intervention(s): None.
Main Outcome Measure(s): Postcryopreservation sperm motility and viability.
Result(s): In oligospermic men, recovery of motile sperm after cryopreservation was possible in only a few out of the 219 samples cry-
opreserved for this problem. Similarly, independent of the reason for which cryopreservation was required, if one basal semen parameter
fell below the 5th percentile of theWorld Health Organization reference values, recovery of motile and viable spermatozoa after thawing
was low. Among samples cryopreserved for cancer, those with testicular cancer showed the lowest basal semen quality and recovery
after thawing. In cases of hematological cancers or other types of cancers, motility recovery was similar to that of non-cancer-
related samples. Receiver operating characteristic analyses demonstrate that basal progressive and total motility predict the recovery
rate of motile sperm after thawing with high accuracy, sensibility and specificity.Use your smartphoneConclusion(s): Our study demonstrates the ability of prefreeze semen parameters to predict
cryosurvival in terms of sensitivity and precision. Using this information, the clinician could
perform appropriate counseling about the future possibilities of fertility for the patient. (Fertil
Steril 2013;100:1555–63. 2013 by American Society for Reproductive Medicine.)
Key Words: Sperm cryopreservation, sperm motility, oligospermia, cancer, sperm viability
Discuss: You can discuss this article with its authors and with other ASRM members at http://
fertstertforum.com/deglinnocentis-semen-cryopreservation-oligozoospermia-cancer/to scan this QR code
and connect to the
discussion forum for
this article now.*
* Download a free QR code scanner by searching for “QR
scanner” in your smartphone’s app store or app marketplace.C ryopreservation of spermatozoais, at present, the most valuableand used way to preserve repro-
Received May 29, 2013; revised July 30, 2013; accept
11, 2013.
S.D.I. has nothing to disclose. E.F. has nothing to d
nothing to disclose. G.L. has nothing to disclose
to disclose. M.M. has nothing to disclose. E.B. h
Reprint requests: MarioMaggi, M.D., Dipartimento d
zione di Fisiopatologia, Clinica, Universita di F
(E-mail: mario.maggi@unifi.it).
Fertility and Sterility® Vol. 100, No. 6, December 201
Copyright ©2013 American Society for Reproductive
http://dx.doi.org/10.1016/j.fertnstert.2013.08.005
VOL. 100 NO. 6 / DECEMBER 2013ductive function in men undergoing
gonadotoxic treatments such as
chemo- or radiotherapies. In addition,ed August 6, 2013; published online September
isclose. A.M. has nothing to disclose. C.K. has
. M.G.F. has nothing to disclose. G.R. has nothing
as nothing to disclose.
i Scienze Biomediche Sperimentali e Cliniche, Se-
irenze, viale Pieraccini 6, I-50139 Firenze, Italy
3 0015-0282/$36.00
Medicine, Published by Elsevier Inc.sperm cryopreservation is increasingly
used in case of other disorders, such
as autoimmune diseases andmyelodys-
plastic syndromes requiring treatments
that may affect reproductive functions.
Moreover, sperm cryopreservation is
offered to patients with severe oligo-
spermia (or even cryptozoospermia) or
ejaculatory disorders with the intent
of using cryopreserved sperm in case
no sperm are found in the ejaculates
on the day of intracytoplasmic sperm1555
ORIGINAL ARTICLE: ANDROLOGYinjection (ICSI) (1) to have sperm available in the event of a
decline in sperm count, which may occur in these patients (2).
Cryopreservation of spermatozoa was introduced in the
early 1960s and is performed with different procedures. In
the last version of the World Health Organization (WHO)
manual for semen analysis, a protocol is indicated, but the
procedure is not standardized (3). The consequences of cryo-
preservation on sperm functions are well-known. Spermato-
zoa may be heavily damaged by freezing-thawing
procedures and total motility, viability, and morphology are
severely affected in most samples (4–7). However, whether
the different types of pathology requiring sperm
cryopreservation may result in a different outcome of sperm
quality at thawing has been studied only for cancer
patients, and results are often controversial (8–14). For
instance, when results of semen cryopreservation from
testicular cancer patients were compared with those of
donors, Said et al. (11) and Hotaling et al. (13) found lower
cryosurvival rates, whereas Hallak et al. (9) did not find
relevant differences. Similarly, whereas Hallak et al. (10)
found lower post-thaw motility recovery in Hodgkin's lym-
phoma patients with respect to healthy donors, motility
reduction in the former category of patients was similar to
that of healthy donors in the study by Hotaling et al. (13).
Outcome of cryopreservation in cases of severe oligospermia
has not been evaluated so far. In addition, whether the ex-
pected decrease in sperm functions is related, or can be pre-
dicted, on the basis of semen quality on the day of
cryopreservation has also been poorly documented. One study
(15) reported that Kruger strict morphology assessment,
among the conventional semen parameters, was the best pre-
dictor of progressive motility recovery after thawing in a
small number of normozoospermic samples. Other studies
(16, 17) evaluating the relationship between prefreezing and
post-thawing semen characteristics demonstrated that higher
concentration and prefreeze motility and fewer abstinence
days are associated with an increased recovery rate in donors
for a sperm bank. In general, it appears that, for normosper-
mic samples, postcryopreservation recovery is related to basal
semen quality; however, sensitivity and specificity of basal
semen parameters in predicting cryosurvival rates have not
been established.
Cryopreserved semen is used in assisted reproductive
techniques (ART) and, in case of low motility recovery, ICSI
is mandatory. Although most studies comparing ICSI using
fresh or thawed spermatozoa do not reveal differences in
reproductive outcome (18, 19), it appears that ICSI
performed with motile spermatozoa gives better results with
respect to immotile ones (20, 21). As a matter of fact, ICSI
performed using cryopreserved spermatozoa from patients
with different types of cancer or pathologies gives rise to
variable clinical pregnancy and live-birth rates (12, 22).
Owing to the detrimental effects of cryopreservation, the
chance of finding motile sperm after thawing to perform the
ICSI procedure is greatly decreased. Such a chance may
decrease even more in pathological conditions (like
testicular cancer and oligospermia) associated with
detrimental effects on semen quality (11, 23–25). In light of
these considerations, prediction of cryopreservation1556outcome on the basis of basal semen quality and type of
pathology for which cryopreservation is required may help
in the management and counseling of these patients.
The present study evaluated sperm motility and viability
recovery rates after thawing and the relationship with pre-
cryopreservation semen quality in 822 semen samples from
men affected by different types of neoplasia, oligospermia,
or other pathologies requiring cryopreservation who discon-
tinued sperm banking. Receiver operating characteristic
(ROC) curves were used to identify the accuracy of the
different semen parameters in predicting motility recovery
rates. Our results demonstrate that the recovery rate of sperm
motility and viability varies among the different pathologies.
In addition, we show that precryopreservation sperm motility
predicts motility recovery with a high accuracy.MATERIALS AND METHODS
Patients
The study was conducted in semen collected from 623 patients
undergoing semen cryopreservation in the Laboratory of An-
drology of the Azienda Ospedaliera-Universitaria of Florence
from 1998 to 2010 who discontinued sperm banking. A total
of 822 semen samples have been collected from these subjects,
as some patients underwent more than one semen collection to
increase the number of cryopreserved straws. Of the 822 sam-
ples, 183 were cryopreserved because of hematological malig-
nancies (122 for Hodgkin's lymphoma, 31 for non–Hodgkin's
lymphoma, 27 for leukemia), 158 for testicular cancer (78 semi-
noma, 16 nonseminomatous germ cell tumors, 64 unknown),
83 for mixed cancer pathologies (15 urinary tract, 26
skeletal-muscle, 17 cerebral, 7 gastrointestinal, and 18 other
types of cancer), 239 for oligospermia, 56 for ejaculatory disor-
ders, 42 for other pathologies (mostly multiple sclerosis and
autoimmune pathologies), and 61 for spinal cord injury (37 us-
ing electroejaculation and 24 with vibratory stimulation). All
cancer patients cryopreserved sperm before initiation of the
antineoplastic treatment. In case of testicular cancer, themajor-
ity of patients underwent cryopreservation after orchiectomy.
Semen samples cryopreserved with baseline 0% viability (n ¼
34), although cryobanked for ethical reasons, were not consid-
ered in the statistical analysis.
All the data provided were collected as part of the routine
clinical procedure, and therefore, according to the Italian law,
approval from the local Ethics Committee was not required. In
addition, informed consent had been obtained from all pa-
tients to use discarded, cryopreserverd sperm for research
purposes.Semen Samples for Cryopreservation
Semen samples were collected the same day of cryopreserva-
tion by masturbation in the laboratory. In exceptional cases,
semen collection was performed at home. With the exception
of spinal cord injury patients, all subjects were asked to
observe 2–7 days of sexual abstinence. After semen analysis
(see below), semen samples were frozen in liquid nitrogen
tanks by a manually controlled freezing procedure according
to Gandini et al. (26) with minimal modifications. Briefly,VOL. 100 NO. 6 / DECEMBER 2013
Fertility and Sterility®samples were diluted 1:1 (vol:vol) by drop-wise addition of
test yolk buffer with glycerol and gentamycin (Irvine scienti-
fic). After equilibration at room temperature for 5–10 mi-
nutes, sperm were loaded in 500 mL high security sperm
straws (Cryo Bio System). Straws were frozen by 8 minutes
of exposure to liquid nitrogen vapors and a final plunge
into liquid nitrogen. Thawing was carried out by transferring
the straw at room temperature for 15 minutes followed by 15
minutes at 37C before evaluations.Pretreatment and Post-Treatment Semen Analysis
Semen analysis was performed according toWHO guidelines (3,
27). Pre- and postcryopreservation sperm motility was assessed
byopticalmicroscopy, according toWHOcriteria (3, 27). Briefly,
sperm motility was evaluated by a Leica DMLS microscope
using a 40 objective. The percentages of progressive,
nonprogressive, and immotile spermatozoa were evaluated on
200 spermatozoa/sample. Sperm viability was evaluated by
using an eosin test according to the WHO manual (3, 27). The
Laboratory of Andrology of the Azienda Ospedaliera-
Universitaria of Florence has been participating in the
UK-NEQAS (United KingdomNational External Quality Assess-
ment Service) external quality control program for semen anal-
ysis since 2005. Themean (SD)percent biases of the laboratory
for the years 2012–2013 were 29.3 (17.5) and 15.6 (12.1),
respectively, for total and progressive motility and 5.7 (1.5)
for sperm concentration (n ¼ 6, data from UK-NEQAS).
Sperm morphology data were not analyzed. Our methods
of assessing sperm morphology varied during the study years
[according to the fourth edition of the WHO manual (27) until
January 2008, and after that, using strict criteria as indicated
in the fifth edition (3)]. Thus, our sperm morphology data did
not lend themselves to the large-scale data analysis needed
for this study.Statistical Analysis
Statistical analysis was performed using Statistical Package
for the Social Sciences version 20.0 (SPSS) for Windows. Re-
covery rates of total and progressive motility were evaluated,
excluding those samples (n ¼ 52) showing 0% basal motility.
The Kolmogorov-Smirnov test was used to test the parameter
distribution. Owing to the abnormal distribution of the pa-TABLE 1
Median (95% confidence interval) of basal semen parameters in the diffe
Volume, mL
Total sperm
count/ejaculate, 3
Total, n ¼ 788 2.80 (2.5–3) 37.50 (30.75–46
Hematological cancer, n ¼ 180 2.40 (2.1–2.5) 96.60 (67.2–129
Testicular cancer, n ¼ 150 3.00 (2.5–3.3) 46.00 (31.5–59.4
Other cancer, n ¼ 83 3.00 (2.6–3.1) 100.80 (60–143)
Other pathologies, n ¼ 42 2.40 (2–3.2) 113.00 (64–183.6
Spinal cord injury, n ¼ 60 1.70 (1.2–2.5) 149.40 (80.6–372
Oligospermia, n ¼ 219 3.20 (3–3.6) 5.40 (4.5–7.14)
Ejaculatory disorder, n ¼ 54 2.55 (1.8–3.4) 44.48 (19.8–100
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VOL. 100 NO. 6 / DECEMBER 2013rameters, statistical significance differences were evaluated
by nonparametric Kruskal-Wallis test. The Mann-Whitney
test was used for comparisons among groups. Correlations be-
tween pre- and postcryopreservation parameters and recov-
ery rates were assessed by Spearman's correlation test.
P< .05 was considered statistically significant. ROC was
used as a binary classifier system to identify the accuracy of
precryopreservation semen parameters in predicting post-
thawing recovery of at least 1% motility.
Data are shown as median values and 95% confidence
limits in the tables and text. The figures have been generated
by SPSS software and showmedian values of the different pa-
rameters and the 10th, 25th, 75th, and 90th percentiles.RESULTS
Effect of Cryopreservation on Sperm Motility and
Viability in the Different Patient Categories
Precryopreservation sperm parameters in the different sub-
groups of patients are shown in Table 1. The median age of
the entire population was 34 years (34–35 years) and did
not significantly differ among the groups. The median time
of cryostorage was 3.01 years (2.9–3.2 years) and did not
differ among the groups (not shown). The overall poorest
semen quality was found in oligospermic patients. Among
patients undergoing cryopreservation for cancer, the lowest
semen quality was observed in testicular cancer (Table 1).
No significant differences were observed between the two
types of germ cell tumors of the testis (seminoma and nonse-
minoma; Supplemental Table 1) and among Hodgkin's, non-
Hodgkin's lymphoma, and leukemia patients (Supplemental
Table 2). Although both total and progressive motility are
low, patients with spinal cord lesions show, on average, an
elevated number of spermatozoa (Table 1).
When the analyzed samples were considered as a whole
(n ¼ 788), cryopreservation determined an average median
recovery of total and progressive sperm motility of 12.4%
(10.67%–15.52%) and 5.8% (4%–7.69%), respectively, and
of sperm viability of 32.8% (30%–35.56%). Figure 1 shows
the average percentage recovery of sperm motility (panel A,
total; and panel B, progressive) and viability (panel C) in the
different subgroups of patients. Nonparametric analysis
(Kruskal-Wallis test) revealed a significant difference among
subgroups for both total and progressive motility and forrent groups of patients undergoing sperm cryobanking.
106
Vitality, % vital
sperm
Progressive
motility, % TMN, 3106
.5) 65.00 (64–68) 31.00 (28–34) 18.15 (12.69–22.78)
.6) 71.00 (70–75) 50.00 (43–52) 57.87 (41.44–82.16)
) 74.00 (70–76) 46.00 (34–54) 26.46 (15.9–37.54)
73.00 (70–76) 44.00 (37–55) 67.58 (29.52–106.26)
) 75.00 (70–80) 56.00 (48–61) 74.72 (40.32–138.62)
) 25.00 (21–32) 11.00 (2–22) 35.23 (11.55–88.8)
50.00 (45–54) 15.00 (10–17) 1.20 (0.63–1.72)
) 65.00 (52–70) 28.00 (17–44) 23.74 (11.6–41.44)
1557
FIGURE 1
Sperm motility and viability recovery in the different groups of subjects undergoing cryopreservation for different reasons. (A) Total motility; (B)
progressive motility; (C) viability. The insets in the three panels show progressive (panel A) and total (panel B) motility and viability (panel C)
percent recovery in patients with seminoma (n ¼ 76) or nonseminoma (n ¼ 14) testicular cancers (upper insets) and Hodgkin's (n ¼ 120), non-
Hodgkin's (n ¼ 30), and leukemia (n ¼ 27) patients (lower insets). OC: other cancers; SCI: spinal cord injury; HC: hematological cancer; O:
oligospermia; ED: ejaculatory disorders; TC: testicular cancer; OP: other pathologies. Data are presented as box plots, showing the median
values as well as the 10th, 25th, 75th, and 90th percentiles. The single points represent the outlier values.
Degl'Innocenti. Oligospermia and cancer sperm cryostorage. Fertil Steril 2013.
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Fertility and Sterility®viability (P< .0001). The highest detrimental effects were
observed in oligozoospermic subjects, where the median
value of recovery approximates 0% for motility and 20%
for viability, with few outliers showing good recovery
(Fig. 1). Interestingly, when patients were divided according
to the 5th percentile of the new WHO reference values (3),
the overall recovery of total (Fig. 2 upper panels) and progres-
sive (Fig. 2 middle panels) motility and viability (Fig. 2 lower
panels) after cryopreservation was the lowest in subjects
showing basal number, total motility, and viability below
the 5th percentile, independent of the pathology for which
cryopreservation was required.
Among the other noncancer pathologies, recovery rates
of sperm motility were quite low in patients with spinal
cord injury (Fig. 1A and B). However, in these patients, the
low recovery rates were compensated for by a high number
of spermatozoa in the ejaculates (Table 1). The highest recov-
ery rates were observed in the subgroup of non-cancer-
related pathologies (Fig. 1).
Among cryopreserved samples for cancer pathologies, the
highest detrimental effects were, not surprisingly, observed in
testicular cancer (Fig. 1), which also showed poor basal semen
quality at cryopreservation (Table 1). When patients with
testicular cancer were categorized according to subtypes
(seminoma vs. nonseminoma), no significant differences
were observed in recovery of motility and viability (Fig. 1, up-
per insets). In the subgroups of hematological and other
(mixed forms) cancers, the overall recovery of motility and
viability was similar to that of mixed, noncancer, pathologies
or ejaculatory disorders subgroups (Fig. 1). When patients
with hematological cancers were divided according to the
subtype (Hodgkin's, non-Hodgkin's, and leukemia), no signif-
icant differences were observed for recovery parameters
(Fig. 1A, lower insets).
Next we calculated the proportion of cryopreserved sam-
ples that recover a sufficient number of progressive motile
spermatozoa to undergo IUI or IVF. We considered 1.5 
106 progressive motile spermatozoa as the minimum require-
ment to undergo IUI and 0.3 106 as theminimum to undergo
IVF. Such parameters were chosen in consideration of the fact
that below 1 106 progressive spermatozoa, the IUI prognosis
is unfavorable (28) and that, according to the current Italian
law, no more than three oocytes can be used for IVF (with
about 0.1  106 progressive motile spermatozoa/oocyte).
Among our cryopreserved samples, 310 (39.3%) recover a
number of progressive motile sperm over 1.5  106 and 375
(47.6%) over 0.3  106. Among the different patient cate-
gories, the higher percentages of samples recovering a number
of progressive motile sperm over 1.5  106 were observed for
hematological (61.1%) and other cancers (85.5%) and the
lowest for oligospermia (5.5%). A similar patternwas observed
when we considered the minimum requirement of progressive
motile spermatozoa for IVF (not shown).Correlations between Pre- and
Postcryopreservation Sperm Parameters
We next evaluated the correlations between post-thaw sperm
motility and viability and precryopreservation sperm param-VOL. 100 NO. 6 / DECEMBER 2013eters (concentration, total and progressive motility, and
viability). As shown in Supplemental Table 3, all post-
thawing parameters as well as the percentage recovery of
viability and total and progressive motility were highly corre-
lated to precryopreservation sperm number, motility, and to-
tal number of motile sperm. The strongest correlations were
observed for precryopreservation progressive motility.
ROC analysis was used to identify the accuracy, sensi-
tivity, and specificity of precryopreservation progressive
(Fig. 3A) and total (Fig. 3B) motility, number of spermato-
zoa/ejaculate (Fig. 3C), and total number of motile sperm
(TMN; Fig. 3D) in predicting total motility recovery of at least
1% after thawing. As can be observed in Figure 3, the accu-
racy was very high for all the parameters (89.0%  0.01%,
P ¼ .000 for progressive motility; 90.5%  0.01%, P ¼ .000
for total motility; 84.0%  0.01%, P ¼ .000 for number of
sperm/ejaculate; and 90.0%  0.005%, P ¼ .000 for TMN).
The figure also shows the sensitivity and the specificity at
the thresholds chosen for the three parameters.DISCUSSION
Semen cryopreservation is widely used to preserve fertility in
case of treatments that may be toxic for the testis. In addition,
the process of cryopreservation is currently used in cases
where a progressive decline of testicular function over time
is suspected, such as in cases of severe oligospermia (1, 2).
Cryopreserved semen is used for several ART procedures,
including ICSI. Whereas procedures such as IUI or IVF-ET
encompass some of the natural barriers of fertilization, the
same cannot be said for ICSI, where the operator selects,
when possible, a motile spermatozoon to inject into the
oocyte, as this is the only way to assure viability and increase
the probability of success (20, 21). We show in the present
study that finding a motile spermatozoon after
cryopreservation may be a hard task in some thawed semen
samples. In particular, motile spermatozoa after thawing are
rarely found in semen samples cryopreserved for severe
oligospermia. Indeed, we show that only a few samples out
of the 239 cryopreserved for this problem recovered motility
and viability in a small percentage of spermatozoa (Fig. 1),
and only a small percentage of them recover enough
progressive motile spermatozoa to perform procedures such
as IUI or IVF. It should be considered that, in addition to loss
of motility and viability, there might be other detrimental
effects after cryopreservation, such as an increase of sperm
DNA fragmentation (11, 29, 30) and decondensation (31) as
well as alterations of other sperm parameters that may be
relevant for the fertilization process (5, 6). All the above
data should be taken into account during patient
management, and clinicians should inform the patients
about the negative impact of cryopreservation on an already
altered semen quality and that ICSI may be required in case
of an ART procedure with cryopreserved semen.
We also show here that cryopreserved semen samples
with basal number, motility, and viability falling below the
5th percentile of the WHO (3) reference value displayed the
lowest recovery rates of motility and viability, independent
of the reason for which cryopreservation was required. In1559
FIGURE 2
Sperm parameters recovery after cryopreservation in subjects with basal semen quality below the 5th percentile of WHO reference limits. Total
(upper panels) and progressive (medium panels) motility and viability (lower panels) recovery (%) in subjects showing number of sperm/
ejaculate (left panels), % total motility (medium panels), and viability (right panels) below the 5th percentile of reference values according to
WHO 5th edition manual (27). Data are presented as box plots, showing the median values as well as the 10th, 25th, 75th, and 90th
percentiles. The single points represent the outlier values. The number of samples for each group is in parentheses.
Degl'Innocenti. Oligospermia and cancer sperm cryostorage. Fertil Steril 2013.
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FIGURE 3
ROC curves for prediction of total motility recovery after cryopreservation. ROC curves for progressive (panel A) and total (panel B) sperm motility,
number of sperm/ejaculate (panel C), and TNM (panel D) for probability of motility recovery after thawing. Sensibility and specificity at the specified
threshold are indicated.
Degl'Innocenti. Oligospermia and cancer sperm cryostorage. Fertil Steril 2013.
Fertility and Sterility®such a situation, even if basal motility and viability are high,
they cannot always guarantee a good recovery of motile
sperm after thawing if the concentration falls below the 5th
percentile of reference values. This result suggests that
intrinsic characteristics of spermatozoa are the major deter-
minant of recovery after thawing. In support of this hypoth-
esis, we show that basal parameters (excluding morphology,
which was not considered in our study for the reasons out-
lined inMaterials andMethods) strictly correlate with motility
recovery after cryopreservation, with basal total and progres-
sive motility showing the stricter correlations. All these pa-
rameters were predictive of motility recovery after thawing
with high values of accuracy, sensitivity, and specificity,
demonstrating that they were of great help in patient coun-
seling. This should be viewed in light of the fact that cryopre-
served semen use for ART is very low among cancer patients
(22, 23).
An open question concerns sperm cryopreservation for
cancer patients. In fact, the probability of recovering motile
sperm after thawing depends on the type of cancer for which
cryopreservation is required, because the impact of a tumorVOL. 100 NO. 6 / DECEMBER 2013on spermatogenesis is quite variable (11, 23, 25). Not
surprisingly, several studies, including ours, report that,
among men undergoing cryopreservation for cancer, those
with testicular cancer show the lowest semen quality and
low recovery rates after cryopreservation (8, 11–13, 22). On
the other hand, there are several factors that may contribute
to lower semen quality in testicular cancer, such as local
production of toxic and inflammatory factors by the tumor,
disruption of the blood-testis barrier, and, not last, the fact
that some risk factors associated with testicular neoplasia
are also associated to infertility, such as cryptorchidism
(32). It should be considered that in our study azoospermic
subjects were not included, and, thus, basal semen parameters
may even be overestimated not only for testicular cancer pa-
tients but also for all other pathologies.
If there is an overall agreement both on basal and post-
cryopreservation semen quality for testicular cancer patients,
the same cannot be said for hematological cancers. Indeed,
while some studies fail to demonstrate alterations of semen
quality in Hodgkin's, non-Hodgkin's, and leukemia patients
(24, 25, 29), other studies have shown alterations of semen1561
ORIGINAL ARTICLE: ANDROLOGYquality in leukemia (9, 13) and/or in Hodgkin's and non-
Hodgkin's diseases (10). In our large study, we did not show
significant alterations of basal semen quality in
hematological or other (mixed types) cancers, and motility
recovery after thawing for both groups was similar to that
of noncancer pathologies and/or ejaculatory disorders. In
the recent paper by Hotaling et al. (13), the lowest recovery
rates of motility after thawing were observed for leukemia
patients, whose performance was even worse than that of
testicular cancer patients. However, although ours and
Hotaling et al.'s (13) study were similar in terms of number
of observations, a direct comparison between these two
studies is not possible, as Hotaling et al. performed sperm
selection or chose treatments that would be able to increase
sperm motility before freezing. In general, a direct
comparison among the different studies on this topic is not
easy because several factors, such as the stage of the
diseases, the copresence of other pathologies or
complications, or the presence of risk factors for infertility
are not systematically recorded. This is an important
limitation of all the studies (including the present one) on
sperm cryopreservation outcome in cancer patients and is
mostly due to the urgency to collect semen for fertility
preservation before gonadotoxic therapies.
The present study has strengths and limitations. One
strength is represented by the fact that this is the first study
showing the results of cryopreservation in a large number
of oligospermic patients. In addition, we report for the first
time ROC curves for the prediction of the outcome of cryopre-
served semen based on prefreeze semen quality. One impor-
tant limitation is that this is a single-center study and thus
the derived information cannot be largely disseminated
because of a lack of standardized protocols. Large multicenter
studies are desirable in the future.
In conclusion, our large study on outcome of cryopreser-
vation indicates that such a procedure does not always guar-
antee recovery of motile sperm for ART procedures in case of
semen pathologies such as severe oligospermia and testicular
cancers or when one basal semen parameter falls below the
5th percentile of the WHO reference value (3). In these cases,
the clinician should perform appropriate counseling about the
future possibilities of fertility for the patient.REFERENCES
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SUPPLEMENTAL TABLE 1
Median (95% confidence interval) of basal semen parameters in patients with testicular cancer according to the histological subtype.
Testicular cancer Volume, mL
Total sperm count/
ejaculate, 3106 Vitality, % vital sperm Progressive motility, % TMN, 3106
Unknown, n ¼ 60 3.20 (2.6–4) 50.95 (20.68–73.6) 75.00 (70–79) 45.50 (27–55) 32.93 (6.82–56.28)
Seminoma, n ¼ 76 2.65 (2–3.2) 36.10 (18–50) 66.00 (62–75) 42.50 (24–55) 17.63 (6.72–27.77)
Mixed nonseminoma, n¼ 14 3.20 (2.5–4.2) 96.00 (54–135) 76.00 (70–84) 59.00 (33–66) 53.63 (25.58–96.77)
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SUPPLEMENTAL TABLE 2
Median (95% confidence interval) of basal semen parameters in patients with hematological cancers according to the cytological subtype.
Hematological cancer Volume, mL
Total sperm
count/ejaculate, 3106
Vitality, % vital
sperm
Progressive
motility, % TMN, 3106
Hodgkin's disease, n ¼ 120 2.20 (1.8–2.5) 79.00 (42–115.5) 73.00 (70–76) 47.00 (38–53) 43.94 (19–70.47)
Non-Hodgkin’s disease, n ¼ 30 2.80 (2.4–3) 122.10 (70.4–207.2) 70.00 (66–75) 49.00 (38–54) 75.67 (52.1–136.4)
Leukemia, n ¼ 27 2.30 (1.6–3.2) 155.00 (54.4–212.5) 70.00 (64–78) 51.00 (40–57) 94.00 (34.15–137.7)
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SUPPLEMENTAL TABLE 3
Correlation coefficients between basal and post-thawing semen parameters.
Basal values
Total sperm count/ejaculate, 3106 Progressive motility, % Vitality, % vital sperm
Post-thawing values % Viability recovery .229a .539a .325a
n ¼ 738 n ¼ 738 n ¼ 738
% Total motility recovery .254a .537a .396a
n ¼ 719 n ¼ 719 n ¼ 717
Note: n indicates the number of observations.
a P< .0001.
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